{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T03:09:10Z","timestamp":1725764950568},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J INFECT DIS"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1086\/503814","type":"journal-article","created":{"date-parts":[[2006,5,2]],"date-time":"2006-05-02T17:02:43Z","timestamp":1146589363000},"page":"1611-1612","source":"Crossref","is-referenced-by-count":10,"title":["Gilbert Syndrome and the Development of Antiretroviral Therapy\u2013Associated Hyperbilirubinemia: Genetic Screening Is Unnecessary"],"prefix":"10.1093","volume":"193","author":[{"given":"Richard\u00a0E.","family":"Nettles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael\u00a0J.","family":"Child","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard\u00a0J.","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Schnittman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"rf1_57","doi-asserted-by":"publisher","DOI":"10.1086\/466531"},{"key":"rf2_58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.231140698"},{"key":"rf3_59","unstructured":"O'Mara E, Randall D, Passarell, et al. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucoronosyl transferase (UGT) 1A1 genotype and safety in healthy human subjects (abstract A-1253, 2002b). Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego: American Society for Microbiology, 2002."},{"key":"rf4_60","unstructured":"Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research. Antiviral Drugs Advisory Committee Meeting. 13 May 2003. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3950T1.DOC. Accessed 5 January 2006."},{"key":"rf5_61","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200408150-00003"},{"key":"rf6_62","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/01.aids.0000166091.39317.99","volume":"19","author":"Johnson M","year":"2005","journal-title":"AIDS"},{"key":"rf7_63","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/archpedi.1990.02150270114039","volume":"144","author":"Newman TB","year":"1990","journal-title":"Am J Dis Child"},{"key":"rf8_64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.14.8170"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/193\/11\/1611\/2637608\/193-11-1611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T10:53:29Z","timestamp":1555584809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1086\/503814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1086\/503814"],"URL":"https:\/\/doi.org\/10.1086\/503814","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}